Press Releases
To stay up to date with our development, sign up for a subscription.
2021
2021-05-10 17:10
Adoption of the profit and loss statement and the balance sheet, the consolidated profit and loss statement and the consolidated balance sheet as well as resolution regarding allocation of profits and discharge from liability The general meeting adopted...
2021-05-06 07:00
Financial Summary This interim report has been prepared in accordance with IFRS with function-based income statement compared with cost-based income statement as previously. January-March 2021 Significant events during the period CEO comments Sedana Medical...
2021-04-15 08:30
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that its Annual Report for 2020 has been published and is available on http://www.sedanamedical.com/investors. The annual report can also be ordered from the company and distributed by post to the...
2021-04-08 08:30
Participation A person who wishes to exercise their voting right at the annual general meeting must: be entered as a shareholder in the share register kept by Euroclear Sweden AB as of the record date Friday 30 April 2021; and have given notice of attendance...
2021-03-31 08:30
The nomination committee of Sedana Medical, which prior to the annual general meeting 2021 is constituted of Karl Tobieson (chairman of the nomination committee and appointed by Linc AB), Thomas Eklund (chairman of the board of directors), Malin Björkmo...
2021-02-25 07:00
Financial Summary This year-end report has been prepared in accordance with IFRS, and comparative periods have been restated. October-December 2020 January-December 2020 Significant events during the period Significant events after the period CEO comments...
2021-02-24 21:00
“Sedana Medical is well on its way in establishing inhaled sedation as a standard treatment in intensive care. I strongly believe in that development and intend to remain a major shareholder. It has been fun and exciting years and it has been a...
2021-02-22 11:00
“AnaConDa was approved for use in children in 2019 in Europe and this study is another important step as it ensures a complete market application for Sedaconda and thus ten years of market exclusivity in the EU. As propofol, due to safety concerns...
2021-02-19 13:30
“Through this application, we cover another important European market ahead of our upcoming launch. If all goes well, we expect to be able to launch in the second half of 2021 in the first 15 European countries for which we have already submitted...
2021-01-20 16:45
“Through this application, we cover another important European market ahead of our upcoming launch. If all goes well, we expect to be able to launch in the second half of 2021 in the first 15 European countries for which we have already submitted...